119 related articles for article (PubMed ID: 36325820)
1. Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia.
Nygård LH; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ
Prostate; 2023 Feb; 83(3):246-258. PubMed ID: 36325820
[TBL] [Abstract][Full Text] [Related]
2. The effect of non-steroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia.
Nygård LH; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ
Prostate; 2017 Jun; 77(9):1029-1035. PubMed ID: 28480542
[TBL] [Abstract][Full Text] [Related]
3. Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort.
Kukko V; Kaipia A; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):373-378. PubMed ID: 29273728
[TBL] [Abstract][Full Text] [Related]
4. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Haring A; Murtola TJ; Talala K; Taari K; Tammela TL; Auvinen A
Scand J Urol; 2017 Feb; 51(1):5-12. PubMed ID: 28084175
[TBL] [Abstract][Full Text] [Related]
5. Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based Cohort.
Vihervuori VJ; Talala K; Taari K; Lahtela J; Tammela TLJ; Auvinen A; Raittinen P; Murtola TJ
Cancer Epidemiol Biomarkers Prev; 2021 May; 30(5):982-989. PubMed ID: 33653815
[TBL] [Abstract][Full Text] [Related]
6. Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan.
Tseng CH
BMC Cancer; 2013 Jan; 13():7. PubMed ID: 23286275
[TBL] [Abstract][Full Text] [Related]
7. Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer.
Murtola TJ; Sälli SM; Talala K; Taari K; Tammela TLJ; Auvinen A
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):453-460. PubMed ID: 30679762
[TBL] [Abstract][Full Text] [Related]
8. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of prostate cancer screening among men using antidiabetic medication.
Vettenranta A; Murtola TJ; Talala K; Taari K; Stenman UH; Tammela TLJ; Auvinen A
Sci Rep; 2021 Apr; 11(1):7363. PubMed ID: 33795720
[TBL] [Abstract][Full Text] [Related]
10. Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population-based cohort study.
Kuo YJ; Sung FC; Hsieh PF; Chang HP; Wu KL; Wu HC
Cancer Med; 2019 May; 8(5):2514-2523. PubMed ID: 30968600
[TBL] [Abstract][Full Text] [Related]
11. Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
Schenk JM; Calip GS; Tangen CM; Goodman P; Parsons JK; Thompson IM; Kristal AR
Am J Epidemiol; 2012 Jul; 176(2):156-63. PubMed ID: 22759721
[TBL] [Abstract][Full Text] [Related]
12. Diabetes treatment and progression of benign prostatic hyperplasia in community-dwelling black and white men.
Sarma AV; St Sauver JL; Hollingsworth JM; Jacobson DJ; McGree ME; Dunn RL; Lieber MM; Jacobsen SJ;
Urology; 2012 Jan; 79(1):102-8. PubMed ID: 22112286
[TBL] [Abstract][Full Text] [Related]
13. Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Murtola TJ; Vihervuori VJ; Lahtela J; Talala K; Taari K; Tammela TL; Auvinen A
Br J Cancer; 2018 May; 118(9):1248-1254. PubMed ID: 29563633
[TBL] [Abstract][Full Text] [Related]
14. Tumor features and survival after radical prostatectomy among antidiabetic drug users.
Joentausta RM; Kujala PM; Visakorpi T; Tammela TL; Murtola TJ
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):367-373. PubMed ID: 27502739
[TBL] [Abstract][Full Text] [Related]
15. Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results.
Beckmann K; Crawley D; Nordström T; Aly M; Olsson H; Lantz A; Binti Abd Jalal N; Garmo H; Adolfsson J; Eklund M; Van Hemelrijck M
JAMA Netw Open; 2019 Nov; 2(11):e1914689. PubMed ID: 31693126
[TBL] [Abstract][Full Text] [Related]
16. Metformin use and long-term risk of benign prostatic hyperplasia: a population-based cohort study.
Nørgaard M; Darvalics B; Thomsen RW
BMJ Open; 2020 Dec; 10(12):e041875. PubMed ID: 33371039
[TBL] [Abstract][Full Text] [Related]
17. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia.
Hammarsten J; Högstedt B
Eur Urol; 2001 Feb; 39(2):151-8. PubMed ID: 11223674
[TBL] [Abstract][Full Text] [Related]
18. Hyperlipidemia is associated with an increased risk of clinical benign prostatic hyperplasia.
Shih HJ; Huang CJ; Lin JA; Kao MC; Fan YC; Tsai PS
Prostate; 2018 Feb; 78(2):113-120. PubMed ID: 29119583
[TBL] [Abstract][Full Text] [Related]
19. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic Use and the Risk of Initiating Medication for Benign Prostate Hyperplasia in Persons With Alzheimer Disease: A Matched Cohort Study.
Orsel K; Taipale H; Raatikainen S; Lampela P; Tolppanen AM; Koponen M; Tanskanen A; Tiihonen J; Gardarsdottir H; Hartikainen S
J Clin Psychopharmacol; 2018 Oct; 38(5):494-497. PubMed ID: 30102630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
